Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 1, 2015
Pharmacy Choice - News - Pharmaceutical Development - September 1, 2015

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/1/15 - AIMT Is Nothing To Sneeze At, AGRX Secured, TiGenix Admired, ICPT Gets FDA Date
PARIS- Agile Therapeutics Inc. has completed patient recruitment in its phase III clinical trial of Twirla, its investigational contraceptive patch. Aimmune Therapeutics Inc. plans to initiate an international phase III registrational trial of AR101 in children and adults with peanut allergy in early 2016.. Peanut allergy is a serious and growing h
Release date- 31082015- ALBANY, N.Y.- AMRI and Saneca Pharmaceuticals, a.s. today announced a strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical ingredients. Based on customer demand, AMRI will prepare the U.S. regulatory filings, and following FDA approval, will manuf
9/1/15 - Asahi Kasei Pharma Corp. - Announcement of listing on the NHI drug price standard and marketing of XIAFLEX
Release date- 31082015- Asahi Kasei Pharma is announcing that XIAFLEX injection for the treatment of Dupuytren's contracture has been listed on the National Health Insurance drug price standard as of today. Asahi Kasei Pharma received rights to develop and market XIAFLEX in Japan through an agreement concluded in March 2011. After conducting a Phas
9/1/15 - Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Gunter Ditzinger named as successor [New Vision (Uganda)]
-Basilea Pharmaceutica Ltd. reports today that Dr. Ingrid Heinze-Krauss will retire after 15 years with the company. Prior to joining Basilea, he held various positions with increasing responsibility at Hoechst Marion Roussel in Frankfurt, Germany and at Novartis Pharma AG in Basel, Switzerland.
9/1/15 - BioTime Management to Participate in Rodman & Renshaw 17th Annual Global Investment Conference [Manufacturing Close - Up]
BioTime reported that BioTime management will present at the Rodman& Renshaw 17th Annual Investment Conference in New York City from 3 to 3:25 p.m. EDT on Thursday, September 10. According to a release, investors will receive an update on BioTime and its subsidiaries. BioTime, a provider of regenerative medicine, is a clinical- stage biotechnology
9/1/15 - Can-Fite Releases Financial Results for 6 Months Ended June 30 [Health & Beauty Close - Up]
Can-Fite BioPharma reported financial results for the six months ended June 30, and updates on its drug development programs. Patent and Trademark Office granted Can-Fite a patent covering the manufacturing process for CF101 in the U.S. and the World Health Organization accepted "piclidenoson" as the proposed generic name for CF101, both important
9/1/15 - Data from C. De Souza et al Provide New Insights into Cancer Drug Discovery (HDAC Inhibitors as Novel Anti-Cancer Therapeutics)
By a News Reporter-Staff News Editor at Cancer Weekly Investigators publish new report on Drugs and Therapies. However, only three HDAC inhibitors have acquired FDA approval till date. Recently, PXD-101 obtained FDA approval for the treatment of Refractory or Relapsed Peripheral T cell lymphoma.
9/1/15 - EQS-News: Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I
EQS Group-News: Polyphor AG/ Key word: Study Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I 01.09. 2015/ 09:00- Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibi
9/1/15 - Heat Biologics Announces Clinical Trial Combining HS-110 and PD-1 Checkpoint Inhibitor in NSCLC
Heat Biologics, Inc., a clinical stage cancer immunotherapy company, announced that it has enrolled the first patient in a Phase 1 b clinical trial investigating the combination of its HS-110 therapeutic vaccine and the Bristol-Myers Squibb PD-1 inhibitor nivolumab in non-small cell lung cancer. Additionally, as the FDA approval of nivolumab and.
9/1/15 - Interim report for Saniona AB (publ) January - June 2015 (new corrected version was published Sept 1th 2015)
Saniona announces its intention to list the company on Nasdaq Stockholm Small Cap in 2016 and appoints CFO Thomas Feldthus as executive vice president to head up the process. Results reported from preclinical development and disclosure of Phase 1 plans for AN363. University of Pennsylvania's Treatment Research Center is granted rights to perf
9/1/15 - Ipsen announces publication in The Lancet Neurology of the results of the phase III randomized study
Release date- 31082015- Paris- Ipsen today announced that The Lancet Neurology has published online at the detailed results from the Ipsen sponsored phase III randomized study showing the efficacy and safety of Dysport in post-stroke or traumatic brain injury patients with upper limb spasticity.
9/1/15 - Neovacs Receives First Regulatory Approvals for a Phase IIb Trial of IFNa-Kinoid in Lupus
NEOVACS, a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that it has been granted first approvals by regulatory agencies and ethics committees in several European countries for a Phase IIb clinical trial of IFN-Kinoid in Systemic Lupus Erythematosus or lupus. Acceptance by competent authorities enabl
9/1/15 - Novartis receives EU approval for Tafinlar and Mekinist, first combination approved for patients with aggressive form of melanoma
Novartis International AG/ Novartis receives EU approval for Tafinlar and Mekinist , first combination approved for patients with aggressive form of melanoma. *Approval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy* Targeted combination...
9/1/15 - Opexa Secures Private Funding for its NMO Orphan Development Program, Including Planned Phase I/II Clinical Study
Opexa Therapeutics, Inc., a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis and neuromyelitis optica, today announced that the Company has entered into a stock purchase agreement with a private investor to fund the Company s NMO program, including its planned Phase I/II tria
9/1/15 - Temple & Fox Chase Cancer Center testing drug for cancer & bone marrow disorders
By a News Reporter-Staff News Editor at Life Science Weekly- Temple University Hospital and Fox Chase Cancer Center are the only two sites in Philadelphia that participated in an international phase I, randomized clinical trial which tested the drug guadecitabine in Myelodysplastic syndromes and acute myelogenous leukemia. Jean-Pierre Issa, MD, D
9/1/15 - Threshold Pharmaceuticals Launches Phase 2 Clinical Trial of Tarloxotinib Bromide [Manufacturing Close - Up]
Threshold Pharmaceuticals reported that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib", for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. According to a release from the company, Tarloxotinib is Threshold's proprietary, hypoxia-activated,..
9/1/15 - US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer
ViroMed Co., Ltd. today announced that the company has received an approval from the US FDA to launch a pivotal Phase III clinical trial utilizing VM202, a proprietary DNA based biopharmaceutical, for chronic non-healing ischemic diabetic foot ulcers. This is the first gene therapy trial specifically targeting ulcers which affects millions of peopl
8/31/15 - "Natural Combination Hormone Replacement Formulations and Therapies" in Patent Application Approval Process (USPTO 20150224117)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Bernick, Brian A.; Cacace, Janice Louise; Persicaner, Peter H.R.; Irani, Neda; Amadio, Julia M., filed on April 20, 2015, was made available online on August 20, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspo
8/31/15 - 60 Degrees Pharmaceuticals to Begin Phase II Clinical Trials in Dengue Fever Patients
By a News Reporter-Staff News Editor at Clinical Trials Week 60 Degrees Pharmaceuticals,, a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital announced that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever
8/31/15 - Adocia and Lilly Begin New Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro in Patients with Type 1 Diabetes [Health & Beauty Close - Up]
Adocia and Eli Lilly and Company reported the initiation of a Phase 1 b clinical trial evaluating BioChaperone Lispro, an ultra- rapid formulation of insulin lispro licensed to Lilly. The formulation uses Adocia's proprietary technology BioChaperone, which is designed to accelerate insulin absorption. "This new clinical study aims to further docum
8/31/15 - Adocia Introduces a Clinical Study on a High Concentration Formulation of the Ultra-Rapid Insulin BioChaperone Lispro [Professional Services Close - Up]
Adocia reported the initiation of a Phase I clinical trial evaluating a new and more concentrated formulation of BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Eli Lilly and Company. Our goal is to test the potential bioequivalence of these two formulations "says Olivier Soula, Adocia's R&D Director and Deputy General
8/31/15 - AFT and Austrian Breast & Colorectal Cancer Study Group Open Global Phase 3 Trial of Targeted Therapy, IBRANCE (palbociclib) [Health & Beauty Close - Up]
The Alliance Foundation Trials, the Austrian Breast& Colorectal Cancer Study Group and Pfizer have launched the Palbociclib Collaborative Adjuvant Study, or PALLAS. The company said the global Phase 3 clinical trial for patients with early-stage breast cancer is being conducted in conjunction with Breast International Group, German Breast Group,...
8/31/15 - Agile Therapeutics Announces Completion of Patient Recruitment in Twirla(R) Phase 3 SECURE Clinical Trial
Agile Therapeutics, Inc. a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that active recruitment has closed in its ongoing single-arm, open-label Phase 3 SECURE clinical trial of Twirla , its investigational contraceptive patch.
8/31/15 - AGTC Announces Achievement of XLRS Patient Enrollment Milestone in Biogen Collaboration [Global Data Point]
AGTC filed an Investigational New Drug application with the U.S. Food and Drug Administration in March to conduct a Phase I/II clinical trial of the company's gene therapy product candidate for the treatment of XLRS. Utilizing technology licensed from the University of Florida, AGTC's XLRS product candidate uses an AAV capsid with surface residues
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement